Messenger RNA: a basis for vaccine technology and cancer treatment

Recent media coverage has highlighted the relatively new technology involving mRNA that has found application in COVID vaccination, but also in the treatment of cancer. The mRNA technology works by sending instructions to cells to produce an antigen or protein, thus enabling the immune system to target cells for destruction. Here, Science Editor Brian Nation compiles a small selection of activity in this important research.

mRNA therapeutics in cancer immunotherapy

Beck JD, Reidenbach D, Salomon N et al. Mol Cancer. 2021 Apr 15; 20 (1): 69. doi: 10.1186/s12943-021-01348-0.

Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer immunotherapy. With the ease of rapid, large-scale Good Manufacturing Practice-grade mRNA production, mRNA is ideally poised not only for off-the-shelf cancer vaccines but also for personalised neoantigen vaccination. The ability to stimulate pattern recognition receptors and thus an anti-viral type of innate immune response equips mRNA-based vaccines with inherent adjuvanticity. 

Log in or register FREE to read the rest

This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text. If you don't already have an account, please register with us completely free of charge.

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024